Communiqués PolyPid Ltd.

Actions

PYPD

IL0011326795

Marché Fermé - Nasdaq Autres places de cotation 22:30:00 17/07/2024			Varia. 5j.	Varia. 1 janv.
3,52 ^USD	-6,38 %		-12,44 %	-7,37 %

02/07	PolyPid enregistre 200 millions de dollars d'actions ordinaires	MT
18/06	PolyPid Ltd. organise une conférence téléphonique pour discuter de l'important besoin médical non satisfait en matière de prévention des infections du site opératoire et fournit une mise à jour sur son essai de phase 3 Shield II en cours.	CI

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

POLYPID : AMENDED AND RESTATED 2012 SHARE OPTION PLAN Form 6 K	02/07	PU
PolyPid Hosts KOL Call to Discuss Significant Unmet Medical Need in Surgical Site Infections Prevention and Provides Update on its Ongoing SHIELD II Phase 3 Trial	18/06	AQ
PolyPid to Host Virtual KOL Event on June 17, 2024, and Provide an Update on the Company’s Ongoing D-PLEX₁₀₀ Phase 3 Trial	10/06	AQ
Polypid : Notice of ANNUAL and EXTRAORDINARY General Meeting of shareholders to be held on July 2, 2024 - Form 6-K	28/05	PU
POLYPID : AMENDED AND RESTATED 2012 SHARE OPTION PLAN - Form 6-K	17/05	PU
PolyPid Provides Corporate Update and Reports First Quarter 2024 Financial Results	08/05	AQ
PolyPid Announces Enrollment of 200th Patient in Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX for the Prevention of Abdominal Colorectal Surgical Site Infections	01/05	AQ
PolyPid to Participate in Citizens JMP Life Sciences Conference	01/05	AQ
PolyPid Announces Enrollment of 200th Patient in Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections	30/04	AQ
PolyPid to Report First Quarter 2024 Financial Results and Operational Highlights on May 8, 2024	24/04	AQ
PolyPid to Participate in Barclays 26th Annual Global Healthcare Conference	28/02	AQ
PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results	14/02	AQ
PolyPid Announces Enrollment of the 100th Patient in the Ongoing SHIELD II Phase 3 Trial	12/02	AQ
PolyPid to Report Fourth Quarter and Full-Year 2023 Financial Results and Operational Highlights on February 14, 2024	31/01	AQ
PolyPid Announces Private Placement for $16 Million in Gross Proceeds	04/01	AQ
PolyPid Provides Corporate Update and Reports Third Quarter 2023 Financial Results	08/11	AQ
PolyPid Announces the Addition of Dr. Nurit Tweezer-Zaks to its Board of Directors	07/11	AQ
PolyPid to Report Third Quarter 2023 Financial Results and Operational Highlights on November 8, 2023	01/11	AQ
PolyPid Regains Compliance with Nasdaq Minimum Closing Bid Price Rule	11/10/23	AQ
POLYPID : AMENDED AND RESTATED 2012 SHARE OPTION PLAN - Form 6-K	10/10/23	PU

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués PolyPid Ltd.

Actions

PYPD

IL0011326795

Communiqués

Filtres